This is a Validated Antibody Database (VAD) review about human CD274, based on 177 published articles (read how Labome selects the articles), using CD274 antibody in all methods. It is aimed to help Labome visitors find the most suited CD274 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
CD274 synonym: B7-H; B7H1; PD-L1; PDCD1L1; PDCD1LG1; PDL1; hPD-L1

Knockout validation
Abcam
domestic rabbit monoclonal (EPR20529)
  • immunohistochemistry knockout validation; mouse; fig 8c
  • flow cytometry; mouse; fig s8b
Abcam CD274 antibody (Abcam, ab213480) was used in immunohistochemistry knockout validation on mouse samples (fig 8c) and in flow cytometry on mouse samples (fig s8b). Mol Cancer (2021) ncbi
Abcam
domestic rabbit monoclonal (28-8)
  • western blot knockout validation; human; loading ...; fig s7j
Abcam CD274 antibody (Abcam, ab205921) was used in western blot knockout validation on human samples (fig s7j). Mol Cancer (2021) ncbi
Abcam
domestic rabbit monoclonal (28-8)
  • western blot knockout validation; human; loading ...; fig 1d
Abcam CD274 antibody (Abcam, ab205921) was used in western blot knockout validation on human samples (fig 1d). Cancer Sci (2021) ncbi
Invitrogen
mouse monoclonal (MIH1)
  • immunocytochemistry knockout validation; human; loading ...; fig 2c
Invitrogen CD274 antibody (eBiosciences, MIH1) was used in immunocytochemistry knockout validation on human samples (fig 2c). Nature (2017) ncbi
others
domestic rabbit monoclonal (SP263)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1c
 CD274 antibody (Roche Diagnostics, SP263) was used in immunohistochemistry - paraffin section on human samples (fig 1c). BMC Cancer (2020) ncbi
BioLegend
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 3b
BioLegend CD274 antibody (BioLegend, 329706) was used in flow cytometry on human samples (fig 3b). Cancers (Basel) (2021) ncbi
mouse monoclonal (MIH2)
  • flow cytometry; human; 1:100; loading ...; fig 6b
BioLegend CD274 antibody (Biolegend, MIH2) was used in flow cytometry on human samples at 1:100 (fig 6b). Nat Commun (2021) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 1h
BioLegend CD274 antibody (Biolegend, 329705) was used in flow cytometry on human samples (fig 1h). Cell Death Dis (2021) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; 1:200; loading ...; fig s7f
BioLegend CD274 antibody (BioLegend, 329706) was used in flow cytometry on human samples at 1:200 (fig s7f). J Immunother Cancer (2021) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; 1:50; loading ...; fig s2c
BioLegend CD274 antibody (BioLegend, 329705) was used in flow cytometry on human samples at 1:50 (fig s2c). Adv Sci (Weinh) (2021) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 3c
BioLegend CD274 antibody (BioLegend, 329705) was used in flow cytometry on human samples (fig 3c). Oncogene (2021) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; mouse; 1:100; fig 1k
BioLegend CD274 antibody (Biolegend, 329736) was used in flow cytometry on mouse samples at 1:100 (fig 1k). Nat Commun (2021) ncbi
mouse monoclonal (29E.2A3)
  • other; mouse; loading ...
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in other on mouse samples . Nat Commun (2020) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig s1c
BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples (fig s1c). BMC Cancer (2020) ncbi
mouse monoclonal (29E.2A3)
  • mass cytometry; human; loading ...; fig 4d
BioLegend CD274 antibody (Biolegend, 329719) was used in mass cytometry on human samples (fig 4d). Front Oncol (2020) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; 1:100; loading ...; fig s20c
BioLegend CD274 antibody (Biolegend, 329724) was used in flow cytometry on human samples at 1:100 (fig s20c). Nat Commun (2020) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig s3
BioLegend CD274 antibody (BioLegend, 329705) was used in flow cytometry on human samples (fig s3). Stem Cell Reports (2020) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig s1a
BioLegend CD274 antibody (BioLegend, 329719) was used in flow cytometry on human samples (fig s1a). Cell (2019) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 6h
BioLegend CD274 antibody (Biolegend, 329717) was used in flow cytometry on human samples (fig 6h). Oncoimmunology (2019) ncbi
mouse monoclonal (MIH2)
  • flow cytometry; human; fig s5c
BioLegend CD274 antibody (Biolegend, 393610) was used in flow cytometry on human samples (fig s5c). J Immunother Cancer (2019) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 4e
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples (fig 4e). Nat Med (2019) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 2c
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples (fig 2c). J Exp Med (2019) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 5b, 5d, e4f
BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples (fig 5b, 5d, e4f). Nature (2019) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; 1:300; loading ...; fig s1b
BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples at 1:300 (fig s1b). JCI Insight (2019) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 1c
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples (fig 1c). Front Immunol (2018) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig s5a
BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples (fig s5a). Cancer Res (2018) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; mouse; 1:200; loading ...; fig s1a
BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on mouse samples at 1:200 (fig s1a). Oncoimmunology (2018) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 4d
BioLegend CD274 antibody (BioLegend, 329708) was used in flow cytometry on human samples (fig 4d). Front Immunol (2018) ncbi
mouse monoclonal (29E.2A3)
  • western blot; human; 1:50; loading ...; fig 1b
BioLegend CD274 antibody (BioLegend, 329708) was used in western blot on human samples at 1:50 (fig 1b). Nat Commun (2018) ncbi
mouse monoclonal (29E.2A3)
  • mass cytometry; human; loading ...; fig 2a
In order to investigate the immune composition of tumor microenvironment in hepatocellular carcinoma, BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in mass cytometry on human samples (fig 2a). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (29E.2A3)
  • immunohistochemistry - frozen section; human; 1:200; fig 5d
BioLegend CD274 antibody (BioLegend, 329702) was used in immunohistochemistry - frozen section on human samples at 1:200 (fig 5d). J Clin Invest (2017) ncbi
mouse monoclonal (29E.2A3)
  • blocking or activating experiments; human; loading ...; fig 6c
In order to implicate retroviral replicating vectors expressing micro30-derived shRNA against Pol II and Pol III as an alternative approach to enhance anti-tumor immunity, BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in blocking or activating experiments on human samples (fig 6c). Mol Ther Nucleic Acids (2017) ncbi
mouse monoclonal (29E.2A3)
  • mass cytometry; human; fig s8
BioLegend CD274 antibody (BioLegend, 329702) was used in mass cytometry on human samples (fig s8). Nature (2017) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 1d
In order to study a mouse model of anti-human PD-L1 for developing new cancer treatments., BioLegend CD274 antibody (Biolegend, 29E.29A3) was used in flow cytometry on human samples (fig 1d). Sci Rep (2017) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; fig s4b
BioLegend CD274 antibody (BioLegend, 29E-2A3) was used in flow cytometry on human samples (fig s4b). JCI Insight (2017) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; fig 2c
In order to propose that decidual stromal cells are a cellular source of BAFF for B cells present in decidua during pregnancy, BioLegend CD274 antibody (Biolegend, 329706) was used in flow cytometry on human samples (fig 2c). Sci Rep (2017) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 5d
BioLegend CD274 antibody (Biolegend, 329714) was used in flow cytometry on human samples (fig 5d). Cell (2016) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 1a
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples (fig 1a). Sci Rep (2016) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples . J Exp Med (2016) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; 1:100; fig 5a
In order to investigate the impact of a cancer-specific MUC1 glycoform, BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples at 1:100 (fig 5a). Nat Immunol (2016) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; fig 4
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples (fig 4). Clin Cancer Res (2017) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig s1
In order to utilize humanized major histocompatibility class I- and class II-deficient NOG mice to assess the antitumor effect of an anti-programmed death-1 antibody, BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples (fig s1). Clin Cancer Res (2017) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; mouse; loading ...; fig 10
In order to report the effects of PD-L1 modulation of T cell function in graft-versus-host disease, BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on mouse samples (fig 10). J Clin Invest (2016) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; fig s6b
In order to test if AML patients treated decitabine have induced expression of cancer testis antigens, BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples (fig s6b). Oncotarget (2016) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; 1:40; fig 1
BioLegend CD274 antibody (BioLegend, 329706) was used in flow cytometry on human samples at 1:40 (fig 1). Mol Med Rep (2016) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; 1:200; fig 2
BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples at 1:200 (fig 2). Nat Commun (2016) ncbi
mouse monoclonal (29E.2A3)
  • blocking or activating experiments; human
  • flow cytometry; human; fig 7
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in blocking or activating experiments on human samples and in flow cytometry on human samples (fig 7). J Immunol Methods (2016) ncbi
mouse monoclonal (29E.2A3)
  • immunohistochemistry; human; 1:100
BioLegend CD274 antibody (Biolegend, 329707) was used in immunohistochemistry on human samples at 1:100. Cancer Res (2015) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; fig 6
BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples (fig 6). PLoS Pathog (2015) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; loading ...; fig 1
In order to investigate the role of granzyme B in T regulatory cell resistance, BioLegend CD274 antibody (BioLegend, 29F.2A3) was used in flow cytometry on human samples (fig 1). J Immunol (2015) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; fig 2
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in flow cytometry on human samples (fig 2). Oncotarget (2015) ncbi
mouse monoclonal (29E.2A3)
  • immunohistochemistry - paraffin section; human; 1:50
BioLegend CD274 antibody (BioLegend, 29E.2A3) was used in immunohistochemistry - paraffin section on human samples at 1:50. J Neuroimmunol (2014) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human; fig 4
BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples (fig 4). Cancer Discov (2015) ncbi
mouse monoclonal (29E.2A3)
  • flow cytometry; human
In order to determine the presence, frequency, association to other immune parameters, and functional properties of circulating CD14(+) cells lacking HLA-DR expression in patients with untreated chronic lymphocytic leukemia, BioLegend CD274 antibody (Biolegend, 29E.2A3) was used in flow cytometry on human samples . Blood (2014) ncbi
mouse monoclonal (29E.2A3)
BioLegend CD274 antibody (BioLegend, #329702) was used . Cancer Res (2014) ncbi
Abcam
domestic rabbit monoclonal (28-8)
  • immunohistochemistry - paraffin section; human; 1:300; loading ...; fig 8a
Abcam CD274 antibody (Abcam, ab205921) was used in immunohistochemistry - paraffin section on human samples at 1:300 (fig 8a). J Clin Med (2021) ncbi
domestic rabbit monoclonal (EPR19759)
  • immunohistochemistry - paraffin section; mouse; 1:500; fig 6e
Abcam CD274 antibody (Abcam, ab213524) was used in immunohistochemistry - paraffin section on mouse samples at 1:500 (fig 6e). J Exp Clin Cancer Res (2021) ncbi
domestic rabbit monoclonal (EPR20529)
  • immunohistochemistry; mouse; 1:50; loading ...; fig 4b
Abcam CD274 antibody (Abcam, ab213480) was used in immunohistochemistry on mouse samples at 1:50 (fig 4b). Theranostics (2021) ncbi
domestic rabbit monoclonal (EPR20529)
  • immunohistochemistry knockout validation; mouse; fig 8c
  • flow cytometry; mouse; fig s8b
Abcam CD274 antibody (Abcam, ab213480) was used in immunohistochemistry knockout validation on mouse samples (fig 8c) and in flow cytometry on mouse samples (fig s8b). Mol Cancer (2021) ncbi
domestic rabbit monoclonal (28-8)
  • western blot knockout validation; human; loading ...; fig s7j
Abcam CD274 antibody (Abcam, ab205921) was used in western blot knockout validation on human samples (fig s7j). Mol Cancer (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; 1:200; fig s3f
Abcam CD274 antibody (Abcam, ab233482) was used in immunohistochemistry - paraffin section on mouse samples at 1:200 (fig s3f). Cell Death Dis (2021) ncbi
domestic rabbit monoclonal (EPR19759)
  • western blot; human; 1:1000; loading ...; fig s7e
Abcam CD274 antibody (Abcam, ab213524) was used in western blot on human samples at 1:1000 (fig s7e). J Immunother Cancer (2021) ncbi
domestic rabbit monoclonal (EPR20529)
  • western blot; mouse; 1:2000; loading ...; fig 2a
Abcam CD274 antibody (Abcam, ab213480) was used in western blot on mouse samples at 1:2000 (fig 2a). Front Oncol (2021) ncbi
domestic rabbit monoclonal (28-8)
  • immunohistochemistry; human; loading ...; fig 1a
Abcam CD274 antibody (Abcam, ab205921) was used in immunohistochemistry on human samples (fig 1a). Cancer Commun (Lond) (2021) ncbi
domestic rabbit monoclonal (28-8)
  • western blot; human; 1:100; loading ...
Abcam CD274 antibody (Abcam, ab205921) was used in western blot on human samples at 1:100. J Immunother Cancer (2021) ncbi
domestic rabbit monoclonal (28-8)
  • flow cytometry; human; 1:1000; loading ...; fig 2j
Abcam CD274 antibody (Abcam, ab205921) was used in flow cytometry on human samples at 1:1000 (fig 2j). Nat Commun (2021) ncbi
domestic rabbit monoclonal (EPR20529)
  • western blot; mouse; loading ...; fig 3c
Abcam CD274 antibody (Abcam, ab213480) was used in western blot on mouse samples (fig 3c). Adv Sci (Weinh) (2021) ncbi
domestic rabbit monoclonal (28-8)
  • western blot; human; 1:100; loading ...; fig 1c
Abcam CD274 antibody (Abcam, ab205921) was used in western blot on human samples at 1:100 (fig 1c). Aging (Albany NY) (2021) ncbi
domestic rabbit monoclonal (28-8)
  • western blot knockout validation; human; loading ...; fig 1d
Abcam CD274 antibody (Abcam, ab205921) was used in western blot knockout validation on human samples (fig 1d). Cancer Sci (2021) ncbi
domestic rabbit monoclonal (28-8)
  • immunohistochemistry; human; 1:5000; loading ...; fig 1
  • western blot; human; loading ...; fig 4a
Abcam CD274 antibody (Abcam, ab205921) was used in immunohistochemistry on human samples at 1:5000 (fig 1) and in western blot on human samples (fig 4a). Cancer Manag Res (2020) ncbi
domestic rabbit monoclonal (EPR19759)
  • western blot; mouse; loading ...; fig 1f
  • western blot; human; loading ...; fig 1d, s2b, s6b
Abcam CD274 antibody (Abcam, ab213524) was used in western blot on mouse samples (fig 1f) and in western blot on human samples (fig 1d, s2b, s6b). Aging (Albany NY) (2020) ncbi
domestic rabbit monoclonal (28-8)
  • immunohistochemistry - paraffin section; human; 1:300; loading ...; fig 3h
Abcam CD274 antibody (Abcam, ab205921) was used in immunohistochemistry - paraffin section on human samples at 1:300 (fig 3h). Cancer Sci (2020) ncbi
domestic rabbit monoclonal (EPR19759)
  • immunohistochemistry - paraffin section; human; loading ...; fig s7d
Abcam CD274 antibody (Abcam, ab213524) was used in immunohistochemistry - paraffin section on human samples (fig s7d). Cell (2019) ncbi
domestic rabbit monoclonal (EPR20529)
  • western blot; mouse; loading ...; fig 3a
Abcam CD274 antibody (Abcam, AB213480) was used in western blot on mouse samples (fig 3a). Cell (2019) ncbi
domestic rabbit monoclonal (28-8)
  • immunohistochemistry - paraffin section; human; 1:100; fig 3a, 3c, 3e
Abcam CD274 antibody (Abcam, ab205921) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 3a, 3c, 3e). Hum Pathol (2019) ncbi
domestic rabbit monoclonal (28-8)
  • western blot; human; 1:3000; loading ...; fig s6
Abcam CD274 antibody (Abcam, ab205921) was used in western blot on human samples at 1:3000 (fig s6). Neurosurgery (2018) ncbi
domestic rabbit monoclonal (28-8)
  • immunohistochemistry; human; 1:100; loading ...; fig s4c
Abcam CD274 antibody (abcam, ab205921) was used in immunohistochemistry on human samples at 1:100 (fig s4c). Nat Commun (2018) ncbi
domestic rabbit monoclonal (28-8)
  • immunohistochemistry - paraffin section; human; 1:400; loading ...; fig 2d
  • western blot; human; 1:2000; loading ...; fig 2d
Abcam CD274 antibody (Abcam, ab205921) was used in immunohistochemistry - paraffin section on human samples at 1:400 (fig 2d) and in western blot on human samples at 1:2000 (fig 2d). Appl Immunohistochem Mol Morphol (2018) ncbi
domestic rabbit monoclonal (28-8)
  • immunohistochemistry - paraffin section; human; 1:100; tbl 4
In order to test if atypical fibroxanthoma is the non-infiltrating precursor lesion of pleomorphic dermal sarcoma, Abcam CD274 antibody (Abcam/Dako, Ab205921) was used in immunohistochemistry - paraffin section on human samples at 1:100 (tbl 4). Oncotarget (2016) ncbi
Invitrogen
mouse monoclonal (MIH1)
  • immunohistochemistry - paraffin section; human; 1:250; loading ...; fig 7g
Invitrogen CD274 antibody (eBioscience, 14-5983-82) was used in immunohistochemistry - paraffin section on human samples at 1:250 (fig 7g). Biomedicines (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - frozen section; mouse; 1:100; loading ...; fig 3a
Invitrogen CD274 antibody (Invitrogen, PA5-20343) was used in immunohistochemistry - frozen section on mouse samples at 1:100 (fig 3a). Cell Mol Gastroenterol Hepatol (2021) ncbi
domestic goat polyclonal
  • immunocytochemistry; human; fig 3d
Invitrogen CD274 antibody (Thermo Fisher, PA5?C18337) was used in immunocytochemistry on human samples (fig 3d). Oncogene (2021) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human; loading ...
Invitrogen CD274 antibody (eBioscience, 12-5983-42) was used in flow cytometry on human samples . Nat Commun (2020) ncbi
mouse monoclonal (MIH1)
  • blocking or activating experiments; mouse; 5 ug/ml; loading ...; fig 3b
Invitrogen CD274 antibody (eBioscience, 16-5983-82) was used in blocking or activating experiments on mouse samples at 5 ug/ml (fig 3b). Aging (Albany NY) (2020) ncbi
mouse monoclonal (MIH1)
  • western blot; human; 1:1000; loading ...; fig 3c
Invitrogen CD274 antibody (ThermoFisher Scientific, MIH1) was used in western blot on human samples at 1:1000 (fig 3c). Am J Cancer Res (2019) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human; loading ...; fig 3b
Invitrogen CD274 antibody (eBioscience, 48-5983-42) was used in flow cytometry on human samples (fig 3b). Cell Rep (2019) ncbi
mouse monoclonal (MIH1)
  • immunocytochemistry knockout validation; human; loading ...; fig 2c
Invitrogen CD274 antibody (eBiosciences, MIH1) was used in immunocytochemistry knockout validation on human samples (fig 2c). Nature (2017) ncbi
domestic rabbit polyclonal
  • immunohistochemistry; human; loading ...; fig 7a
In order to investigate the tumor microenvironment in tertiary lymphoid organs of prostate cancer patients, Invitrogen CD274 antibody (Invitrogen, PA5-28115) was used in immunohistochemistry on human samples (fig 7a). Front Immunol (2017) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human; loading ...; fig 3b
In order to evaluate the effectiveness of adoptive natural killer cell therapy against the pulmonary metastasis of Ewing sarcoma, Invitrogen CD274 antibody (eBiosciences, MIH1) was used in flow cytometry on human samples (fig 3b). Oncoimmunology (2017) ncbi
mouse monoclonal (MIH1)
In order to demonstrate that PD-1 inhibits T cell function primarily by inactivating CD28 signaling, Invitrogen CD274 antibody (eBioscience, 12-5983) was used . Science (2017) ncbi
domestic rabbit polyclonal
  • immunoprecipitation; rat; loading ...; fig 2c
  • immunocytochemistry; rat; loading ...; fig 5b
  • western blot; rat; loading ...; fig 3b
In order to assess the critical role of programmed death protein 1/programmed death-ligand 1 in the polarization of microglia during intracerebral hemorrhage-induced secondary brain injury, Invitrogen CD274 antibody (Thermo Fisher, PA5-20343) was used in immunoprecipitation on rat samples (fig 2c), in immunocytochemistry on rat samples (fig 5b) and in western blot on rat samples (fig 3b). J Neuroinflammation (2017) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human; tbl 3
In order to document and describe lymphocyte predominant cells from lymph nodes involved in nodular lymphocyte predominant Hodgkin lymphoma, Invitrogen CD274 antibody (eBioscience, MIH1) was used in flow cytometry on human samples (tbl 3). Am J Pathol (2017) ncbi
mouse monoclonal (MIH1)
  • blocking or activating experiments; human; 10 ug/ml; fig 5
Invitrogen CD274 antibody (eBioscience, 16-5983) was used in blocking or activating experiments on human samples at 10 ug/ml (fig 5). Oncoimmunology (2016) ncbi
mouse monoclonal (MIH1)
  • blocking or activating experiments; mouse; loading ...; fig 10
In order to report the effects of PD-L1 modulation of T cell function in graft-versus-host disease, Invitrogen CD274 antibody (eBioscience, MIH1) was used in blocking or activating experiments on mouse samples (fig 10). J Clin Invest (2016) ncbi
domestic rabbit polyclonal
  • western blot; mouse; fig 1
  • western blot; human; fig 1
In order to characterize regulation of PD-L1 in melanoma by HDAC6, Invitrogen CD274 antibody (Thermo Scientific, PA5-28115) was used in western blot on mouse samples (fig 1) and in western blot on human samples (fig 1). Mol Oncol (2016) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human; fig 1
In order to study the use of bispecific T cell engager, Invitrogen CD274 antibody (eBiosciences, M1H1) was used in flow cytometry on human samples (fig 1). PLoS ONE (2015) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; mouse
In order to study immune escape from CD8+ T cell killing mediated by PD-L1 expression on retrovirus-infected cells, Invitrogen CD274 antibody (eBioscience, MIH1) was used in flow cytometry on mouse samples . PLoS Pathog (2015) ncbi
mouse monoclonal (MIH1)
  • immunohistochemistry - frozen section; human; 1:50; fig 2
In order to investigate factors that regulate delayed-type hypersensitivity, Invitrogen CD274 antibody (eBioscience, MIH1) was used in immunohistochemistry - frozen section on human samples at 1:50 (fig 2). F1000Res (2015) ncbi
mouse monoclonal (MIH1)
  • western blot; mouse; 1:500
Invitrogen CD274 antibody (eBioscience, M1H1) was used in western blot on mouse samples at 1:500. Science (2015) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human; fig s4
Invitrogen CD274 antibody (eBioscience, 17-5983) was used in flow cytometry on human samples (fig s4). Stem Cell Reports (2015) ncbi
mouse monoclonal (MIH1)
  • blocking or activating experiments; human; fig 4
In order to examine the role of lymphocyte activation gene-3 during HIV infection, Invitrogen CD274 antibody (eBioscience, MIH1) was used in blocking or activating experiments on human samples (fig 4). J Immunol (2015) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human; fig 5
In order to describe the phenotype and functional potential of metastatic differentiated thyroid cancer-associated PD-1 positive T cells, Invitrogen CD274 antibody (eBioscience, MIH1) was used in flow cytometry on human samples (fig 5). Cancer Immunol Res (2015) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human
In order to discuss how inflammation contributes to pulmonary arterial hypertension, Invitrogen CD274 antibody (eBioscience, clone MIH1) was used in flow cytometry on human samples . Chest (2015) ncbi
mouse monoclonal (MIH1)
  • immunohistochemistry; human
Invitrogen CD274 antibody (eBioscience, MIH1) was used in immunohistochemistry on human samples . Cancer (2011) ncbi
mouse monoclonal (MIH1)
  • immunohistochemistry - frozen section; human; fig 1
  • flow cytometry; human
Invitrogen CD274 antibody (eBioscience, MIH1) was used in immunohistochemistry - frozen section on human samples (fig 1) and in flow cytometry on human samples . Arthritis Rheum (2010) ncbi
mouse monoclonal (MIH1)
  • blocking or activating experiments; human; 10 ug/ml; fig 6
In order to use flow cytometry to characterize cells from patients with relapsing-remitting acute or stable multiple sclerosis, Invitrogen CD274 antibody (eBioscience, MIH1) was used in blocking or activating experiments on human samples at 10 ug/ml (fig 6). J Immunol (2009) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human; tbl 2
In order to investigate the impact of HSP-27 treatment on monocyte differentiation into dendritic cells, Invitrogen CD274 antibody (eBioscience, MIH1) was used in flow cytometry on human samples (tbl 2). Eur J Immunol (2007) ncbi
OriGene
mouse monoclonal (UMAB228)
  • western blot; human; loading ...; fig 3a, 4e
OriGene CD274 antibody (Origene, UMAB228) was used in western blot on human samples (fig 3a, 4e). Oncogene (2021) ncbi
Sino Biological
domestic rabbit monoclonal (015)
  • immunohistochemistry - paraffin section; human
  • ELISA; human
  • western blot; human; 1:5000; loading ...; fig 4c
  • immunohistochemistry; domestic rabbit
  • ELISA; domestic rabbit
Sino Biological CD274 antibody (Sino Biological, 10084-R015-50) was used in immunohistochemistry - paraffin section on human samples , in ELISA on human samples , in western blot on human samples at 1:5000 (fig 4c), in immunohistochemistry on domestic rabbit samples and in ELISA on domestic rabbit samples . EMBO Mol Med (2017) ncbi
domestic rabbit monoclonal (015)
  • immunohistochemistry; domestic rabbit
  • ELISA; domestic rabbit
  • immunohistochemistry - paraffin section; human; fig 2
Sino Biological CD274 antibody (Sinobiological, 10084-R015) was used in immunohistochemistry on domestic rabbit samples , in ELISA on domestic rabbit samples and in immunohistochemistry - paraffin section on human samples (fig 2). Oncotarget (2015) ncbi
domestic rabbit monoclonal (015)
  • immunohistochemistry; domestic rabbit
  • ELISA; domestic rabbit
  • immunohistochemistry - paraffin section; human; 1:200
  • immunohistochemistry; human
  • ELISA; human
Sino Biological CD274 antibody (Sino Biological, 10084-R015) was used in immunohistochemistry on domestic rabbit samples , in ELISA on domestic rabbit samples , in immunohistochemistry - paraffin section on human samples at 1:200, in immunohistochemistry on human samples and in ELISA on human samples . PLoS ONE (2014) ncbi
Novus Biologicals
domestic rabbit polyclonal (6H12)
  • immunohistochemistry - paraffin section; mouse; fig 6
Novus Biologicals CD274 antibody (Novus, NBP1-76769) was used in immunohistochemistry - paraffin section on mouse samples (fig 6). Front Cell Dev Biol (2021) ncbi
Bio-Rad
domestic goat polyclonal
  • immunohistochemistry - paraffin section; human; 1:50; fig 2
Bio-Rad CD274 antibody (AbD Serotec, AHP2128) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 2). Breast Cancer Res (2016) ncbi
Cell Signaling Technology
domestic rabbit monoclonal (E1L3N)
  • western blot; human; 1:1000; loading ...; fig 4a
  • western blot; mouse; fig 4b
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, 13,684) was used in western blot on human samples at 1:1000 (fig 4a) and in western blot on mouse samples (fig 4b). J Exp Clin Cancer Res (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; loading ...; fig 2d
Cell Signaling Technology CD274 antibody (Cell Signaling Technologies, 13684S) was used in immunohistochemistry on human samples (fig 2d). Commun Biol (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; loading ...; fig 6e
Cell Signaling Technology CD274 antibody (CST, 13684) was used in western blot on human samples (fig 6e). Signal Transduct Target Ther (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; 1:1000; loading ...; fig 1f
  • immunocytochemistry; mouse; 1:50; fig 3k
  • western blot; mouse; 1:1000; fig 1f, s3d
Cell Signaling Technology CD274 antibody (CST, 13684) was used in western blot on human samples at 1:1000 (fig 1f), in immunocytochemistry on mouse samples at 1:50 (fig 3k) and in western blot on mouse samples at 1:1000 (fig 1f, s3d). Cell Death Dis (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; 1:100; loading ...; fig 5e
  • western blot; human; 1:1000; loading ...; fig 4a, 4c
Cell Signaling Technology CD274 antibody (CST, 13684S) was used in immunohistochemistry on human samples at 1:100 (fig 5e) and in western blot on human samples at 1:1000 (fig 4a, 4c). Int J Biol Sci (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 10 ug/ml; loading ...; fig 1e
Cell Signaling Technology CD274 antibody (CST, E1L3N) was used in immunohistochemistry - paraffin section on human samples at 10 ug/ml (fig 1e). J Immunother Cancer (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; 1:50; loading ...; fig 2a
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, 13684S) was used in immunohistochemistry on human samples at 1:50 (fig 2a). BMC Cancer (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; loading ...; fig s7
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, E1L3N) was used in immunohistochemistry on human samples (fig s7). Sci Rep (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 1b
  • western blot; human; 1:1000; loading ...; fig 4c
Cell Signaling Technology CD274 antibody (Cell Signaling, E1L3N) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 1b) and in western blot on human samples at 1:1000 (fig 4c). Cancer Sci (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; loading ...; fig 1a, 2c, 2l
Cell Signaling Technology CD274 antibody (CST, 13684) was used in western blot on human samples (fig 1a, 2c, 2l). Adv Sci (Weinh) (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; 1:2000; loading ...; fig 3b, 3d
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in western blot on human samples at 1:2000 (fig 3b, 3d). Neuro Oncol (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; 1:400; loading ...; fig 2c
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, 13684S) was used in immunohistochemistry on human samples at 1:400 (fig 2c). Nat Cancer (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; 1:400; loading ...
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in immunohistochemistry on human samples at 1:400. J Immunother Cancer (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 2e
Cell Signaling Technology CD274 antibody (cell signaling, E1L3N) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 2e). Front Oncol (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 5h
  • western blot; human; 1:1000; loading ...; fig 2e, 3b, 4b
  • western blot; mouse; 1:1000; loading ...; fig 2f, 7d
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 5h), in western blot on human samples at 1:1000 (fig 2e, 3b, 4b) and in western blot on mouse samples at 1:1000 (fig 2f, 7d). Nat Commun (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; 1:50; loading ...
Cell Signaling Technology CD274 antibody (Cell signaling, E1L3N) was used in immunohistochemistry on human samples at 1:50. Ann Hematol (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; 1:1000; loading ...; fig 3b, 3c
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, 13684S) was used in western blot on human samples at 1:1000 (fig 3b, 3c). Cell Biosci (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 1e, 1f
  • flow cytometry; human; loading ...; fig 3b
Cell Signaling Technology CD274 antibody (CST, E1L3N) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 1e, 1f) and in flow cytometry on human samples (fig 3b). Oncol Lett (2021) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; 1:500; loading ...; fig 4n
Cell Signaling Technology CD274 antibody (Cell Signaling Technologies, 13684) was used in western blot on human samples at 1:500 (fig 4n). Nature (2020) ncbi
mouse monoclonal (405.9A11)
  • immunohistochemistry; mouse; 1:500; loading ...; fig 7d
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, 29122) was used in immunohistochemistry on mouse samples at 1:500 (fig 7d). JCI Insight (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:1000; loading ...; fig 6s1b
Cell Signaling Technology CD274 antibody (Cell Signaling, E1L3) was used in immunohistochemistry - paraffin section on human samples at 1:1000 (fig 6s1b). elife (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; loading ...; fig 6b
Cell Signaling Technology CD274 antibody (Cell signaling, E1L3N) was used in western blot on human samples (fig 6b). Theranostics (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; loading ...
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, E1L3N) was used in immunohistochemistry on human samples . Nat Commun (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 1d
Cell Signaling Technology CD274 antibody (Cell Signaling, E1L3N) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1d). Breast Cancer Res (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; 1:1000; loading ...; fig 5a
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684S) was used in western blot on human samples at 1:1000 (fig 5a). Theranostics (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; loading ...; fig 3
Cell Signaling Technology CD274 antibody (Cell Signaling, E1L3N) was used in immunohistochemistry - paraffin section on human samples (fig 3). Acta Neuropathol Commun (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; loading ...; fig 3
Cell Signaling Technology CD274 antibody (Cell Signaling, E1L3N) was used in immunohistochemistry - paraffin section on human samples (fig 3). Front Immunol (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunocytochemistry; human; loading ...; fig 9c
  • western blot; human; 1:1000; loading ...; fig 9b
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, 13684) was used in immunocytochemistry on human samples (fig 9c) and in western blot on human samples at 1:1000 (fig 9b). J Virol (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; tbl 4
Cell Signaling Technology CD274 antibody (Cell signaling, E1L3N) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 4). Medicine (Baltimore) (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; 1:100; loading ...; fig 4
Cell Signaling Technology CD274 antibody (CellSignalingtechnology, Ozyme, Saint Quentin en Yveline, France, E1L3N) was used in immunohistochemistry on human samples at 1:100 (fig 4). Microorganisms (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; mouse; 1:1000; loading ...; fig 8i
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in immunohistochemistry - paraffin section on mouse samples at 1:1000 (fig 8i). Cancer Cell (2020) ncbi
domestic rabbit monoclonal (E1J2J™)
  • immunocytochemistry; human; 1:100; loading ...; fig 6
Cell Signaling Technology CD274 antibody (Cell Signaling, 15165) was used in immunocytochemistry on human samples at 1:100 (fig 6). Aging (Albany NY) (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunocytochemistry; human; 1:100; loading ...; fig 6
  • western blot; human; loading ...; fig 1a
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in immunocytochemistry on human samples at 1:100 (fig 6) and in western blot on human samples (fig 1a). Aging (Albany NY) (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 3a
  • western blot; human; loading ...; fig 4f, 6a
Cell Signaling Technology CD274 antibody (Cell Signaling, E1L3N) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 3a) and in western blot on human samples (fig 4f, 6a). Cancer Sci (2020) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; loading ...; fig 2a
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, E1L3N) was used in western blot on human samples (fig 2a). J Exp Clin Cancer Res (2019) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig s1b
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684S) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig s1b). J Immunother Cancer (2019) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; 1:1000; loading ...; fig 3a
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, 13684) was used in western blot on human samples at 1:1000 (fig 3a). Am J Cancer Res (2019) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; loading ...
Cell Signaling Technology CD274 antibody (CST, 13684S) was used in immunohistochemistry on human samples . Cell (2019) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:800; loading ...; fig 1f
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in immunohistochemistry - paraffin section on human samples at 1:800 (fig 1f). Nat Med (2019) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; 1:100; loading ...; fig 1c
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in immunohistochemistry on human samples at 1:100 (fig 1c). JCO Precis Oncol (2019) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; 1:100; loading ...; fig 1c
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in immunohistochemistry on human samples at 1:100 (fig 1c). Brain Res Bull (2019) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; 1:100; loading ...; fig 1c
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in immunohistochemistry on human samples at 1:100 (fig 1c). Adv Healthc Mater (2019) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; 1:100; loading ...; fig 1c
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in immunohistochemistry on human samples at 1:100 (fig 1c). Cell Rep (2019) ncbi
domestic rabbit monoclonal (E1L3N)
  • mass cytometry; human; loading ...; fig 2j
  • immunohistochemistry; human; loading ...; fig 6f
Cell Signaling Technology CD274 antibody (Cell Signaling Technologie, 13684) was used in mass cytometry on human samples (fig 2j) and in immunohistochemistry on human samples (fig 6f). Cell (2019) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; loading ...; fig 1b
Cell Signaling Technology CD274 antibody (Cell Signaling technology, 13684T) was used in western blot on human samples (fig 1b). Cell (2019) ncbi
domestic rabbit monoclonal (E1L3N)
  • other; human; 1:40; loading ...; fig 2d
  • western blot; human; 1:1000; loading ...; fig 5b
  • immunohistochemistry - paraffin section; mouse; 1:200; fig s1c
Cell Signaling Technology CD274 antibody (cell Signaling, E1L3N) was used in other on human samples at 1:40 (fig 2d), in western blot on human samples at 1:1000 (fig 5b) and in immunohistochemistry - paraffin section on mouse samples at 1:200 (fig s1c). JCI Insight (2019) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunocytochemistry; human; 1:50; fig 3a
Cell Signaling Technology CD274 antibody (Cell Signalling Technology, E1L3N) was used in immunocytochemistry on human samples at 1:50 (fig 3a). PLoS ONE (2019) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunocytochemistry; human; 1:200; loading ...; fig 5a
  • western blot; human; 1:1000; loading ...; fig 3b
Cell Signaling Technology CD274 antibody (Cell Signaling, E1L3N) was used in immunocytochemistry on human samples at 1:200 (fig 5a) and in western blot on human samples at 1:1000 (fig 3b). Br J Cancer (2019) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 10 ug/ml; loading ...; fig s4
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684S) was used in immunohistochemistry - paraffin section on human samples at 10 ug/ml (fig s4). Cell (2018) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; loading ...; fig 1g
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684S) was used in western blot on human samples (fig 1g). Oncoimmunology (2018) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunoprecipitation; human; 1:200; loading ...; fig 2b
  • immunocytochemistry; human; 1:200; loading ...; fig 3e
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, 13684) was used in immunoprecipitation on human samples at 1:200 (fig 2b) and in immunocytochemistry on human samples at 1:200 (fig 3e). Mol Cell (2018) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 1
  • western blot; human; 1:1000; loading ...; fig s6
Cell Signaling Technology CD274 antibody (Cell Signaling, E1L3N) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 1) and in western blot on human samples at 1:1000 (fig s6). Neurosurgery (2018) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; loading ...; fig 6b
Cell Signaling Technology CD274 antibody (Cell Signaling Technologies, 13684) was used in western blot on human samples (fig 6b). Oncoimmunology (2018) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 1a
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, 13684) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 1a). Oncogene (2018) ncbi
domestic rabbit monoclonal (E1L3N)
  • other; human; loading ...; fig 4c
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in other on human samples (fig 4c). Cancer Cell (2018) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; loading ...; fig 5a
Cell Signaling Technology CD274 antibody (Cell Signaling, E1L3N) was used in immunohistochemistry - paraffin section on human samples (fig 5a). J Clin Invest (2018) ncbi
domestic rabbit monoclonal (E1L3N)
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used . Nature (2018) ncbi
domestic rabbit monoclonal (E1J2J™)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 2b
  • western blot; human; 1:2000; loading ...; fig 2b
Cell Signaling Technology CD274 antibody (Cell Signaling, 15165) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2b) and in western blot on human samples at 1:2000 (fig 2b). Appl Immunohistochem Mol Morphol (2018) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 2a
  • western blot; human; 1:2000; loading ...; fig 2a
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2a) and in western blot on human samples at 1:2000 (fig 2a). Appl Immunohistochem Mol Morphol (2018) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; mouse; fig s4b
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, 13684) was used in immunohistochemistry on mouse samples (fig s4b). Clin Cancer Res (2017) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; fig s5c
In order to find a role for IL-4 in promoting breast cancer aggressiveness, Cell Signaling Technology CD274 antibody (CST, E1L3N) was used in western blot on human samples (fig s5c). Cancer Res (2017) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 3a
  • western blot; human; 1:5000
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 3a) and in western blot on human samples at 1:5000. EMBO Mol Med (2017) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; loading ...; fig s2b
Cell Signaling Technology CD274 antibody (Cell Signaling, E1L3N) was used in immunohistochemistry - paraffin section on human samples (fig s2b). Oncoimmunology (2017) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:400; loading ...; fig 3c
In order to investigate the role of PD-L1 and T-cell infiltration in metastatic high-grade osteosarcoma, Cell Signaling Technology CD274 antibody (Cell signaling, E1L3 N) was used in immunohistochemistry - paraffin section on human samples at 1:400 (fig 3c). Cancer Immunol Immunother (2017) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:800; loading ...; fig 2c
In order to analyze small-cell lung cancer samples for CD274 mutations, Cell Signaling Technology CD274 antibody (Cell Signaling T, E1L3N) was used in immunohistochemistry - paraffin section on human samples at 1:800 (fig 2c). Clin Cancer Res (2017) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; fig 1a
In order to assess programmed cell death 1 and programmed cell death ligand 1 expression in patients with extranodal natural killer/T cell lymphoma, Cell Signaling Technology CD274 antibody (Cell Signaling, E1L3N) was used in immunohistochemistry - paraffin section on human samples (fig 1a). Virchows Arch (2016) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; 1:30; loading ...; fig s8c
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in immunohistochemistry on human samples at 1:30 (fig s8c). Nat Commun (2016) ncbi
mouse monoclonal (405.9A11)
  • immunohistochemistry - paraffin section; human; loading ...
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, 405.9A11) was used in immunohistochemistry - paraffin section on human samples . JAMA Oncol (2017) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; loading ...
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, E1L3N) was used in immunohistochemistry - paraffin section on human samples . JAMA Oncol (2017) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
Cell Signaling Technology CD274 antibody (Cell Signaling Tech, 13684S) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1). Nat Commun (2016) ncbi
domestic rabbit monoclonal (E1L3N)
  • western blot; human; 1:1000; fig 5e
In order to discuss the role of myeloid cells in pancreatic cancer pathogenesis, Cell Signaling Technology CD274 antibody (cell signalling, 13684) was used in western blot on human samples at 1:1000 (fig 5e). Gut (2017) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
In order to gain insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade by analysis of immune signatures in longitudinal tumor samples, Cell Signaling Technology CD274 antibody (Cell Signaling Technology, 13684) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1). Cancer Discov (2016) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; fig 1A
Cell Signaling Technology CD274 antibody (CST, 13684) was used in immunohistochemistry - paraffin section on human samples (fig 1A). PLoS ONE (2016) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - frozen section; human
  • western blot; human; fig 1
Cell Signaling Technology CD274 antibody (Cell signaling, E1L3NVR) was used in immunohistochemistry - frozen section on human samples and in western blot on human samples (fig 1). Int J Cancer (2016) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; 1:500; fig s8
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, 13684) was used in immunohistochemistry on human samples at 1:500 (fig s8). Nat Commun (2016) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry; human; 1:50; tbl 2
In order to evaluate the reliance on EBV or NF-kappaB signaling instead of B-cell receptor signaling in regards to complete phenotypic characterization of PTLD, Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in immunohistochemistry on human samples at 1:50 (tbl 2). Hematol Oncol (2017) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; loading ...; fig 2
Cell Signaling Technology CD274 antibody (Cell Signaling Technology, E1L3N) was used in immunohistochemistry - paraffin section on human samples (fig 2). J Immunother Cancer (2015) ncbi
domestic rabbit monoclonal (E1L3N)
  • immunohistochemistry - paraffin section; human; 1:500; loading ...; fig 1h
Cell Signaling Technology CD274 antibody (Cell Signaling, 13684) was used in immunohistochemistry - paraffin section on human samples at 1:500 (fig 1h). PLoS ONE (2015) ncbi
Ventana
domestic rabbit monoclonal (SP263)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1c
Ventana CD274 antibody (Ventana, SP263) was used in immunohistochemistry - paraffin section on human samples (fig 1c). BMC Cancer (2021) ncbi
domestic rabbit monoclonal (SP263)
  • immunohistochemistry - paraffin section; human; loading ...; fig 3a
Ventana CD274 antibody (Ventana, SP263) was used in immunohistochemistry - paraffin section on human samples (fig 3a). Sci Rep (2021) ncbi
domestic rabbit monoclonal (SP263)
  • immunohistochemistry; human; loading ...; tbl 2
Ventana CD274 antibody (Ventana, SP263) was used in immunohistochemistry on human samples (tbl 2). Lung India (2020) ncbi
domestic rabbit monoclonal (SP263)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1f
Ventana CD274 antibody (Ventana, SP263) was used in immunohistochemistry - paraffin section on human samples (fig 1f). BMC Cancer (2019) ncbi
domestic rabbit monoclonal (SP263)
  • immunohistochemistry; human; fig 5a
Ventana CD274 antibody (Ventana, SP263) was used in immunohistochemistry on human samples (fig 5a). Blood (2018) ncbi
domestic rabbit monoclonal (SP263)
  • immunohistochemistry - paraffin section; human; 1:4; loading ...; fig 1
Ventana CD274 antibody (Ventana, SP263) was used in immunohistochemistry - paraffin section on human samples at 1:4 (fig 1). Neurosurgery (2018) ncbi
domestic rabbit monoclonal (SP263)
  • immunohistochemistry - paraffin section; human; fig 2d
  • western blot; human; 1:300; fig 1b
Ventana CD274 antibody (Ventana Medical Systems, 790-4905) was used in immunohistochemistry - paraffin section on human samples (fig 2d) and in western blot on human samples at 1:300 (fig 1b). Am J Pathol (2018) ncbi
domestic rabbit monoclonal (SP263)
  • immunohistochemistry - paraffin section; human; loading ...; fig 2f
  • western blot; human; 1:500; loading ...; fig 2f
Ventana CD274 antibody (Ventana, 790-4905) was used in immunohistochemistry - paraffin section on human samples (fig 2f) and in western blot on human samples at 1:500 (fig 2f). Appl Immunohistochem Mol Morphol (2018) ncbi
domestic rabbit monoclonal (SP263)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1
Ventana CD274 antibody (Ventana, SP263) was used in immunohistochemistry - paraffin section on human samples (fig 1). PLoS ONE (2016) ncbi
domestic rabbit monoclonal (SP142)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1
Ventana CD274 antibody (Ventana, SP142) was used in immunohistochemistry - paraffin section on human samples (fig 1). PLoS ONE (2016) ncbi
Biocare Medical
monoclonal (CAL10)
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 1
Biocare Medical CD274 antibody (Biocare, CAL10) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 1). Neurosurgery (2018) ncbi
Beckman Coulter
mouse monoclonal (PDL1.3.1)
  • flow cytometry; human; fig 3
Beckman Coulter CD274 antibody (Beckman Coulter, A78884) was used in flow cytometry on human samples (fig 3). Stem Cell Res Ther (2016) ncbi
BD Biosciences
mouse monoclonal (MIH1)
  • flow cytometry; human; loading ...; fig 1d
BD Biosciences CD274 antibody (BD Biosciences, 558065) was used in flow cytometry on human samples (fig 1d). Aging (Albany NY) (2021) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; mouse; loading ...; fig 1b
BD Biosciences CD274 antibody (BD Biosciences, MIH1) was used in flow cytometry on mouse samples (fig 1b). Cancer Sci (2019) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human; loading ...; fig s5a
BD Biosciences CD274 antibody (BD, MIH1) was used in flow cytometry on human samples (fig s5a). JCI Insight (2018) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human; loading ...
In order to assess the effects of sialic acid blockade on dendritic cells, BD Biosciences CD274 antibody (BD Bioscience, MIH1) was used in flow cytometry on human samples . Immunol Cell Biol (2017) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human; fig 1
BD Biosciences CD274 antibody (BD Pharmigen, 558017) was used in flow cytometry on human samples (fig 1). Oncoimmunology (2016) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human; fig st1
In order to find cell-surface markers specific to human neutrophils, BD Biosciences CD274 antibody (BD, 557924) was used in flow cytometry on human samples (fig st1). Exp Cell Res (2016) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human; fig 2
In order to characterize regulation of PD-L1 in melanoma by HDAC6, BD Biosciences CD274 antibody (BDBioscience, 557924) was used in flow cytometry on human samples (fig 2). Mol Oncol (2016) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human; fig 7
BD Biosciences CD274 antibody (BD Biosciences, 558017) was used in flow cytometry on human samples (fig 7). Retrovirology (2015) ncbi
mouse monoclonal (MIH1)
  • flow cytometry; human
BD Biosciences CD274 antibody (Becton Dickinson, 558065) was used in flow cytometry on human samples . Mol Oncol (2015) ncbi
ProSci
domestic rabbit polyclonal
  • western blot; mouse; fig 1c
ProSci CD274 antibody (ProSci, 4059) was used in western blot on mouse samples (fig 1c). Sci Rep (2019) ncbi
Articles Reviewed
  1. Sekino Y, Pham Q, Kobatake K, Kitano H, Ikeda K, Goto K, et al. KIFC1 Is Associated with Basal Type, Cisplatin Resistance, PD-L1 Expression and Poor Prognosis in Bladder Cancer. J Clin Med. 2021;10: pubmed publisher
  2. Li C, Shen Q, Zhang P, Wang T, Liu W, Li R, et al. Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells. J Exp Clin Cancer Res. 2021;40:315 pubmed publisher
  3. Lavoie R, Gargollo P, Ahmed M, Kim Y, Baer E, Phelps D, et al. Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion. Cancers (Basel). 2021;13: pubmed publisher
  4. Bamodu O, Wang Y, Yeh C, Ho C, Chiang Y, Kao W, et al. Concomitant High Apoptosis Inhibitor of Macrophage (AIM) and Low Prostate-Specific Antigen (PSA) Indicates Activated T Cell-Mediated Anticancer Immunity, Enhance Sensitivity to Pembrolizumab, and Elicit Good Prognosis in Prostate Cancer. Biomedicines. 2021;9: pubmed publisher
  5. Jiang Y, Yuan Y, Chen M, Li S, Bai J, Zhang Y, et al. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression. Theranostics. 2021;11:9162-9176 pubmed publisher
  6. Li E, Huang X, Zhang G, Liang T. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. J Exp Clin Cancer Res. 2021;40:279 pubmed publisher
  7. Strait A, Woolaver R, Hall S, Young C, Karam S, Jimeno A, et al. Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma. Commun Biol. 2021;4:1005 pubmed publisher
  8. Liu Z, Wang T, She Y, Wu K, Gu S, Li L, et al. N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer. Mol Cancer. 2021;20:105 pubmed publisher
  9. Moreira T, Mangani D, Cox L, Leibowitz J, Lobo E, Oliveira M, et al. PD-L1+ and XCR1+ dendritic cells are region-specific regulators of gut homeostasis. Nat Commun. 2021;12:4907 pubmed publisher
  10. Zhu Q, Ma Y, Liang J, Wei Z, Li M, Zhang Y, et al. AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma. Signal Transduct Target Ther. 2021;6:299 pubmed publisher
  11. Xu P, Xiong W, Lin Y, Fan L, Pan H, Li Y. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression. Cell Death Dis. 2021;12:779 pubmed publisher
  12. Mao C, Jiang S, Wang X, Tao S, Jiang B, Mao C, et al. BCAR1 plays critical roles in the formation and immunoevasion of invasive circulating tumor cells in lung adenocarcinoma. Int J Biol Sci. 2021;17:2461-2475 pubmed publisher
  13. Wu S, Xiao Y, Wei J, Xu X, Jin X, Hu X, et al. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. J Immunother Cancer. 2021;9: pubmed publisher
  14. Kang C, Song C, Kim N, Nam R, Choi S, Yu J, et al. The Enhanced Inhibitory Effect of Estrogen on PD-L1 Expression Following Nrf2 Deficiency in the AOM/DSS Model of Colitis-Associated Cancer. Front Oncol. 2021;11:679324 pubmed publisher
  15. Lauret Marie Joseph E, Kirilovsky A, Lecoester B, El Sissy C, Boullerot L, Rangan L, et al. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. J Immunother Cancer. 2021;9: pubmed publisher
  16. Pham Q, Taniyama D, Sekino Y, Akabane S, Babasaki T, Kobayashi G, et al. Clinicopathologic features of TDO2 overexpression in renal cell carcinoma. BMC Cancer. 2021;21:737 pubmed publisher
  17. Zhang J, Qi J, Wei H, Lei Y, Yu H, Liu N, et al. TGFβ1 in Cancer-Associated Fibroblasts Is Associated With Progression and Radiosensitivity in Small-Cell Lung Cancer. Front Cell Dev Biol. 2021;9:667645 pubmed publisher
  18. Lomphithak T, Akara Amornthum P, Murakami K, Hashimoto M, Usubuchi H, Iwabuchi E, et al. Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma. Sci Rep. 2021;11:11743 pubmed publisher
  19. Muranushi R, Araki K, Yokobori T, Chingunjav B, Hoshino K, Dolgormaa G, et al. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. Cancer Sci. 2021;112:3314-3323 pubmed publisher
  20. Zhang H, Xia Y, Wang F, Luo M, Yang K, Liang S, et al. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression. Adv Sci (Weinh). 2021;8:2003404 pubmed publisher
  21. Gusyatiner O, Bady P, Pham M, Lei Y, Park J, Daniel R, et al. BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma. Neuro Oncol. 2021;23:1680-1692 pubmed publisher
  22. Yang Y, Xia L, Wu Y, Zhou H, Chen X, Li H, et al. Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer. Cancer Commun (Lond). 2021;41:511-527 pubmed publisher
  23. Morel K, Sheahan A, Burkhart D, Baca S, Boufaied N, Liu Y, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2:444-456 pubmed publisher
  24. Go D, Lee S, Lee S, Woo S, Kim K, Kim K, et al. Programmed Death Ligand 1-Expressing Classical Dendritic Cells MitigateHelicobacter-Induced Gastritis. Cell Mol Gastroenterol Hepatol. 2021;12:715-739 pubmed publisher
  25. Zhou J, Pei X, Yang Y, Wang Z, Gao W, Ye R, et al. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma. J Immunother Cancer. 2021;9: pubmed publisher
  26. Pezzuto F, Lunardi F, Vedovelli L, Fortarezza F, Urso L, Grosso F, et al. P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment. Front Oncol. 2021;11:653497 pubmed publisher
  27. Kim S, Kim J, Kim S, Lee Y, Han J, Baek W, et al. PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma. BMC Cancer. 2021;21:336 pubmed publisher
  28. Shang M, Yang H, Yang R, Chen T, Fu Y, Li Y, et al. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation. Nat Commun. 2021;12:1940 pubmed publisher
  29. Liu X, Jiang J, Liao Y, Tang I, Zheng E, Qiu W, et al. Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. Adv Sci (Weinh). 2021;8:2002147 pubmed publisher
  30. Brune M, Stussi G, Lundberg P, Vela V, Heim D, Manz M, et al. Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. Ann Hematol. 2021;100:1169-1179 pubmed publisher
  31. Peng Q, Zhu X, Li C, Xin P, Zheng Y, Liu S. APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells. Aging (Albany NY). 2021;13:7199-7210 pubmed publisher
  32. Liu Y, Li X, Zhang H, Zhang M, Wei Y. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer. Oncogene. 2021;40:2230-2242 pubmed publisher
  33. Arenas E, Martínez Sabadell A, Rius Ruiz I, Román Alonso M, Escorihuela M, Luque A, et al. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nat Commun. 2021;12:1237 pubmed publisher
  34. Watanabe M, Kuwata T, Setsuda A, Tokunaga M, Kaito A, Sugita S, et al. Molecular and pathological analyses of gastric stump cancer by next-generation sequencing and immunohistochemistry. Sci Rep. 2021;11:4165 pubmed publisher
  35. Jiang X, Xu Y, Ren H, Jiang J, Wudu M, Wang Q, et al. KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K/PD-L1 axis activity. Cell Biosci. 2020;10:139 pubmed publisher
  36. Kuroki H, Anraku T, Kazama A, Shirono Y, Bilim V, Tomita Y. Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment. Oncol Lett. 2021;21:64 pubmed publisher
  37. Wang C, Weng M, Xia S, Zhang M, Chen C, Tang J, et al. Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer. Cancer Sci. 2021;112:178-193 pubmed publisher
  38. Cui P, Jing P, Liu X, Xu W. Prognostic Significance of PD-L1 Expression and Its Tumor-Intrinsic Functions in Hypopharyngeal Squamous Cell Carcinoma. Cancer Manag Res. 2020;12:5893-5902 pubmed publisher
  39. Li Z, Zhang H, Huang Y, Huang J, Sun P, Zhou N, et al. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nat Commun. 2020;11:3806 pubmed publisher
  40. Banik S, Pedram K, Wisnovsky S, Ahn G, Riley N, Bertozzi C. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature. 2020;584:291-297 pubmed publisher
  41. Li H, Lu C, Zhang H, Hu Q, Zhang J, Cuevas I, et al. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI Insight. 2020;5: pubmed publisher
  42. Robbins Y, Greene S, Friedman J, Clavijo P, Van Waes C, Fabian K, et al. Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. elife. 2020;9: pubmed publisher
  43. Morrissey M, Byrne R, Nulty C, McCabe N, Lynam Lennon N, Butler C, et al. The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation. BMC Cancer. 2020;20:566 pubmed publisher
  44. Liao T, Lin C, Jiang J, Yang S, Teng H, Yang M. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer. Theranostics. 2020;10:6095-6112 pubmed publisher
  45. Liu X, Kong W, Peterson C, McGrail D, Hoang A, Zhang X, et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun. 2020;11:2135 pubmed publisher
  46. Kim M, Chung Y, Kim H, Woo J, Ahn S, Park S. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Res. 2020;22:32 pubmed publisher
  47. Wu W, Jing D, Meng Z, Hu B, Zhong B, Deng X, et al. FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity. Theranostics. 2020;10:2859-2871 pubmed publisher
  48. Mohme M, Maire C, Schliffke S, Joosse S, Alawi M, Matschke J, et al. Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape. Acta Neuropathol Commun. 2020;8:28 pubmed publisher
  49. Fu W, Wang W, Li H, Jiao Y, Weng J, Huo R, et al. High Dimensional Mass Cytometry Analysis Reveals Characteristics of the Immunosuppressive Microenvironment in Diffuse Astrocytomas. Front Oncol. 2020;10:78 pubmed publisher
  50. Herrera Rios D, Mughal S, Teuber Hanselmann S, Pierscianek D, Sucker A, Jansen P, et al. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain. Front Immunol. 2020;11:120 pubmed publisher
  51. Kumar M, Guleria B, Swamy S, Soni S. Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer. Lung India. 2020;37:145-150 pubmed publisher
  52. Asha K, Balfe N, Sharma Walia N. Concurrent Control of the Kaposi's Sarcoma-Associated Herpesvirus Life Cycle through Chromatin Modulation and Host Hedgehog Signaling: a New Prospect for the Therapeutic Potential of Lipoxin A4. J Virol. 2020;94: pubmed publisher
  53. Tsukagoshi M, Yokobori T, Yajima T, Maeno T, Shimizu K, Mogi A, et al. Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. Medicine (Baltimore). 2020;99:e19059 pubmed publisher
  54. Noh B, Kwak J, Eom D. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma. BMC Cancer. 2020;20:58 pubmed publisher
  55. Sellier Y, Marliot F, Bessières B, Stirnemann J, Encha Razavi F, Guilleminot T, et al. Adaptive and Innate Immune Cells in Fetal Human Cytomegalovirus-Infected Brains. Microorganisms. 2020;8: pubmed publisher
  56. Mosaheb M, Dobrikova E, Brown M, Yang Y, Cable J, Okada H, et al. Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nat Commun. 2020;11:524 pubmed publisher
  57. Liu Z, Wen J, Wu C, Hu C, Wang J, Bao Q, et al. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma. Aging (Albany NY). 2020;12:1213-1236 pubmed publisher
  58. Orgaz J, Crosas Molist E, Sadok A, Perdrix Rosell A, Maiques O, Rodriguez Hernandez I, et al. Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. Cancer Cell. 2020;37:85-103.e9 pubmed publisher
  59. Kobayashi G, Sentani K, Babasaki T, Sekino Y, Shigematsu Y, Hayashi T, et al. Claspin overexpression is associated with high-grade histology and poor prognosis in renal cell carcinoma. Cancer Sci. 2020;111:1020-1027 pubmed publisher
  60. Verdura S, Cuyàs E, Cortada E, Brunet J, Lopez Bonet E, Martin Castillo B, et al. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging (Albany NY). 2020;12:8-34 pubmed publisher
  61. Suzuki D, Flahou C, Yoshikawa N, Stirblyte I, Hayashi Y, Sawaguchi A, et al. iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity. Stem Cell Reports. 2020;14:49-59 pubmed publisher
  62. Shima T, Shimoda M, Shigenobu T, Ohtsuka T, Nishimura T, Emoto K, et al. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma. Cancer Sci. 2020;111:727-738 pubmed publisher
  63. Zhang Q, He Y, Luo N, Patel S, Han Y, Gao R, et al. Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. Cell. 2019;179:829-845.e20 pubmed publisher
  64. Cao Y, Chan K, Xiao G, Chen Y, Qiu X, Hao H, et al. Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma. BMC Cancer. 2019;19:1022 pubmed publisher
  65. Thiem A, Hesbacher S, Kneitz H, di Primio T, Heppt M, Hermanns H, et al. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. J Exp Clin Cancer Res. 2019;38:397 pubmed publisher
  66. Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng Q, et al. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. J Immunother Cancer. 2019;7:233 pubmed publisher
  67. Jordan S, Tung N, Casanova Acebes M, Chang C, Cantoni C, Zhang D, et al. Dietary Intake Regulates the Circulating Inflammatory Monocyte Pool. Cell. 2019;178:1102-1114.e17 pubmed publisher
  68. Findlay E, Currie A, Zhang A, Ovciarikova J, Young L, Stevens H, et al. Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy. Oncoimmunology. 2019;8:1608106 pubmed publisher
  69. Wei J, Luo C, Wang Y, Guo Y, Dai H, Tong C, et al. PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. J Immunother Cancer. 2019;7:209 pubmed publisher
  70. Wang S, Yao F, Lu X, Li Q, Su Z, Lee J, et al. Temozolomide promotes immune escape of GBM cells via upregulating PD-L1. Am J Cancer Res. 2019;9:1161-1171 pubmed
  71. Celis Gutierrez J, Blattmann P, Zhai Y, Jarmuzynski N, Ruminski K, Gregoire C, et al. Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. Cell Rep. 2019;27:3315-3330.e7 pubmed publisher
  72. Lee J, Park S, Park H, Kim S, Lee J, Lee J, et al. Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma. Cell. 2019;177:1842-1857.e21 pubmed publisher
  73. Yang W, Lee K, Srivastava R, Kuo F, Krishna C, Chowell D, et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med. 2019;25:767-775 pubmed publisher
  74. Middha S, Yaeger R, Shia J, Stadler Z, King S, Guercio S, et al. Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. JCO Precis Oncol. 2019;3: pubmed publisher
  75. Gao X, Wu D, Dou L, Zhang H, Huang L, Zeng J, et al. Protective effects of mesenchymal stem cells overexpressing extracellular regulating kinase 1/2 against stroke in rats. Brain Res Bull. 2019;149:42-52 pubmed publisher
  76. Haney M, Klyachko N, Harrison E, Zhao Y, Kabanov A, Batrakova E. TPP1 Delivery to Lysosomes with Extracellular Vesicles and their Enhanced Brain Distribution in the Animal Model of Batten Disease. Adv Healthc Mater. 2019;8:e1801271 pubmed publisher
  77. Genga R, Kernfeld E, Parsi K, Parsons T, Ziller M, Maehr R. Single-Cell RNA-Sequencing-Based CRISPRi Screening Resolves Molecular Drivers of Early Human Endoderm Development. Cell Rep. 2019;27:708-718.e10 pubmed publisher
  78. Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci Rep. 2019;9:6136 pubmed publisher
  79. Wagner J, Rapsomaniki M, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019;177:1330-1345.e18 pubmed publisher
  80. Hammerich L, Marron T, Upadhyay R, Svensson Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25:814-824 pubmed publisher
  81. Poggio M, Hu T, Pai C, Chu B, BELAIR C, Chang A, et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019;177:414-427.e13 pubmed publisher
  82. Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;: pubmed publisher
  83. Mendoza J, Escalante N, Jude K, Sotolongo Bellon J, Su L, Horton T, et al. Structure of the IFNγ receptor complex guides design of biased agonists. Nature. 2019;567:56-60 pubmed publisher
  84. Geng Y, Liu X, Liang J, Habiel D, Kulur V, Coelho A, et al. PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight. 2019;4: pubmed publisher
  85. Po J, Ma Y, Balakrishna B, Brungs D, Azimi F, De Souza P, et al. Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status. PLoS ONE. 2019;14:e0211866 pubmed publisher
  86. Martin V, Chiriaco C, Modica C, Acquadro A, Cortese M, Galimi F, et al. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours. Br J Cancer. 2019;120:527-536 pubmed publisher
  87. Yahata T, Mizoguchi M, Kimura A, Orimo T, Toujima S, Kuninaka Y, et al. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression. Cancer Sci. 2019;110:1279-1292 pubmed publisher
  88. Richardson J, Armbruster N, Günter M, Henes J, Autenrieth S. Staphylococcus aureus PSM Peptides Modulate Human Monocyte-Derived Dendritic Cells to Prime Regulatory T Cells. Front Immunol. 2018;9:2603 pubmed publisher
  89. Andre P, Denis C, Soulas C, Bourbon Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018;175:1731-1743.e13 pubmed publisher
  90. Barreta A, Sarian L, Ferracini A, Costa L, Mazzola P, de Angelo Andrade L, et al. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis. Hum Pathol. 2019;85:72-81 pubmed publisher
  91. Wu B, Sun X, Gupta H, Yuan B, Li J, Ge F, et al. Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer. Oncoimmunology. 2018;7:e1500107 pubmed publisher
  92. Cha J, Yang W, Xia W, Wei Y, Chan L, Lim S, et al. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018;71:606-620.e7 pubmed publisher
  93. Song T, Nairismägi M, Laurensia Y, Lim J, Tan J, Li Z, et al. Oncogenic activation of STAT3 pathway drives PD-L1 expression in natural killer/T cell lymphoma. Blood. 2018;: pubmed publisher
  94. Pratt D, Dominah G, Lobel G, Obungu A, Lynes J, Sanchez V, et al. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma. Neurosurgery. 2018;: pubmed publisher
  95. Jung I, Kim Y, Yu H, Lee M, Kim S, Lee J. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells. Cancer Res. 2018;78:4692-4703 pubmed publisher
  96. Luo N, Formisano L, Gonzalez Ericsson P, Sanchez V, Dean P, Opalenik S, et al. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 2018;7:e1438106 pubmed publisher
  97. Capuano C, Battella S, Pighi C, Franchitti L, Turriziani O, Morrone S, et al. Tumor-Targeting Anti-CD20 Antibodies Mediate In Vitro Expansion of Memory Natural Killer Cells: Impact of CD16 Affinity Ligation Conditions and In Vivo Priming. Front Immunol. 2018;9:1031 pubmed publisher
  98. Zhu B, Tang L, Chen S, Yin C, Peng S, Li X, et al. Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy. Oncogene. 2018;37:4941-4954 pubmed publisher
  99. Hsu J, Xia W, Hsu Y, Chan L, Yu W, Cha J, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018;9:1908 pubmed publisher
  100. Haffner M, Guner G, Taheri D, Netto G, Palsgrove D, Zheng Q, et al. Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. Am J Pathol. 2018;188:1478-1485 pubmed publisher
  101. Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10 pubmed publisher
  102. Liu R, Merola J, Manes T, Qin L, Tietjen G, Lopez Giraldez F, et al. Interferon-γ converts human microvascular pericytes into negative regulators of alloimmunity through induction of indoleamine 2,3-dioxygenase 1. JCI Insight. 2018;3: pubmed publisher
  103. Lin H, Wei S, Hurt E, Green M, Zhao L, Vatan L, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018;128:805-815 pubmed publisher
  104. Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira N, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91-95 pubmed publisher
  105. Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101-105 pubmed publisher
  106. Parra E, Villalobos P, Mino B, Rodriguez Canales J. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol. 2018;26:83-93 pubmed publisher
  107. Xu C, Zhang Y, Rolfe P, Hernández V, Guzman W, Kradjian G, et al. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models. Clin Cancer Res. 2017;23:5869-5880 pubmed publisher
  108. Chew V, Lai L, Pan L, Lim C, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900-E5909 pubmed publisher
  109. Watanabe R, Shirai T, Namkoong H, Zhang H, Berry G, Wallis B, et al. Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. J Clin Invest. 2017;127:2725-2738 pubmed publisher
  110. Garcia Hernandez M, Uribe Uribe N, Espinosa González R, Kast W, Khader S, Rangel Moreno J. A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression. Front Immunol. 2017;8:563 pubmed publisher
  111. Tong A, Hashem H, Eid S, Allen F, Kingsley D, Huang A. Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma. Oncoimmunology. 2017;6:e1303586 pubmed publisher
  112. Gaggianesi M, Turdo A, Chinnici A, Lipari E, Apuzzo T, Benfante A, et al. IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition. Cancer Res. 2017;77:3268-3279 pubmed publisher
  113. Lin A, Twitty C, Burnett R, Hofacre A, Mitchell L, Espinoza F, et al. Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro. Mol Ther Nucleic Acids. 2017;6:221-232 pubmed publisher
  114. Lu X, Horner J, Paul E, Shang X, Troncoso P, Deng P, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543:728-732 pubmed publisher
  115. Hui E, Cheung J, Zhu J, Su X, Taylor M, Wallweber H, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355:1428-1433 pubmed publisher
  116. Guo M, Tomoshige K, Meister M, Muley T, Fukazawa T, Tsuchiya T, et al. Gene signature driving invasive mucinous adenocarcinoma of the lung. EMBO Mol Med. 2017;9:462-481 pubmed publisher
  117. Huang A, Peng D, Guo H, Ben Y, Zuo X, Wu F, et al. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies. Sci Rep. 2017;7:42687 pubmed publisher
  118. Buisseret L, Garaud S, de Wind A, Van den Eynden G, Boisson A, Solinas C, et al. Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology. 2017;6:e1257452 pubmed publisher
  119. Wu J, Sun L, Li H, Shen H, Zhai W, Yu Z, et al. Roles of programmed death protein 1/programmed death-ligand 1 in secondary brain injury after intracerebral hemorrhage in rats: selective modulation of microglia polarization to anti-inflammatory phenotype. J Neuroinflammation. 2017;14:36 pubmed publisher
  120. Martin Gayo E, Cronin J, Hickman T, Ouyang Z, Lindqvist M, Kolb K, et al. Circulating CXCR5+CXCR3+PD-1lo Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth. JCI Insight. 2017;2:e89574 pubmed publisher
  121. Lundell A, Nordström I, Andersson K, Lundqvist C, Telemo E, Nava S, et al. IFN type I and II induce BAFF secretion from human decidual stromal cells. Sci Rep. 2017;7:39904 pubmed publisher
  122. Fromm J, Thomas A, Wood B. Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. Am J Pathol. 2017;187:304-317 pubmed publisher
  123. Bull C, Collado Camps E, Kers Rebel E, Heise T, Søndergaard J, den Brok M, et al. Metabolic sialic acid blockade lowers the activation threshold of moDCs for TLR stimulation. Immunol Cell Biol. 2017;95:408-415 pubmed publisher
  124. Vranic S, Ghosh N, Kimbrough J, Bilalovic N, Bender R, Arguello D, et al. PD-L1 Status in Refractory Lymphomas. PLoS ONE. 2016;11:e0166266 pubmed publisher
  125. Sundara Y, Kostine M, Cleven A, Bovee J, Schilham M, Cleton Jansen A. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother. 2017;66:119-128 pubmed publisher
  126. Roybal K, Williams J, Morsut L, Rupp L, Kolinko I, Choe J, et al. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell. 2016;167:419-432.e16 pubmed publisher
  127. An L, Gorman J, Stephens G, Swerdlow B, Warrener P, Bonnell J, et al. Complement C5a induces PD-L1 expression and acts in synergy with LPS through Erk1/2 and JNK signaling pathways. Sci Rep. 2016;6:33346 pubmed publisher
  128. Tagawa T, Albanese M, Bouvet M, Moosmann A, Mautner J, Heissmeyer V, et al. Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing. J Exp Med. 2016;213:2065-80 pubmed publisher
  129. George J, Saito M, Tsuta K, Iwakawa R, Shiraishi K, Scheel A, et al. Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer. Clin Cancer Res. 2017;23:1220-1226 pubmed publisher
  130. Kim W, Jung H, Nam S, Kim T, Heo D, Kim C, et al. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. Virchows Arch. 2016;469:581-590 pubmed
  131. Beatson R, Tajadura Ortega V, Achkova D, Picco G, Tsourouktsoglou T, Klausing S, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016;17:1273-1281 pubmed publisher
  132. Li C, Lim S, Xia W, Lee H, Chan L, Kuo C, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632 pubmed publisher
  133. Gaule P, Smithy J, Toki M, Rehman J, Patell Socha F, Cougot D, et al. A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. JAMA Oncol. 2017;3:256-259 pubmed publisher
  134. Camilleri E, Gustafson M, Dudakovic A, Riester S, Garces C, Paradise C, et al. Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production. Stem Cell Res Ther. 2016;7:107 pubmed publisher
  135. Shi L, Fu T, Guan B, Chen J, Blando J, Allison J, et al. Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined ?-CTLA-4+?-PD-1 therapy. Nat Commun. 2016;7:12335 pubmed publisher
  136. Seifert A, Zeng S, Zhang J, Kim T, Cohen N, Beckman M, et al. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res. 2017;23:454-465 pubmed publisher
  137. Franzese O, Palermo B, Di Donna C, Sperduti I, Ferraresi V, Stabile H, et al. Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. Oncoimmunology. 2016;5:e1114203 pubmed publisher
  138. Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, et al. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Clin Cancer Res. 2017;23:149-158 pubmed publisher
  139. Zhang Y, Velez Delgado A, Mathew E, Li D, Mendez F, Flannagan K, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 2017;66:124-136 pubmed publisher
  140. Chen P, Roh W, Reuben A, Cooper Z, Spencer C, Prieto P, et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016;6:827-37 pubmed publisher
  141. Saha A, O Connor R, Thangavelu G, Lovitch S, Dandamudi D, Wilson C, et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016;126:2642-60 pubmed publisher
  142. Duchnowska R, Pęksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B, et al. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res. 2016;18:43 pubmed publisher
  143. Ameratunga M, Asadi K, Lin X, Walkiewicz M, Murone C, Knight S, et al. PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. PLoS ONE. 2016;11:e0153954 pubmed publisher
  144. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed publisher
  145. Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer. 2016;139:396-403 pubmed publisher
  146. Helbig D, Ihle M, Pütz K, Tantcheva Poor I, Mauch C, Büttner R, et al. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget. 2016;7:21763-74 pubmed publisher
  147. Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Blagitko Dorfs N, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7:12840-56 pubmed publisher
  148. Zhang J, Wang C, Zhang P, Wang X, Chen J, Yang J, et al. Expression of programmed death 1 ligand 1 on periodontal tissue cells as a possible protective feedback mechanism against periodontal tissue destruction. Mol Med Rep. 2016;13:2423-30 pubmed publisher
  149. Johnson D, Estrada M, Salgado R, Sanchez V, Doxie D, Opalenik S, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582 pubmed publisher
  150. Menter T, Dickenmann M, Juskevicius D, Steiger J, Dirnhofer S, Tzankov A. Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling. Hematol Oncol. 2017;35:187-197 pubmed publisher
  151. Jutz S, Leitner J, Schmetterer K, Doel Perez I, Majdic O, Grabmeier Pfistershammer K, et al. Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1. J Immunol Methods. 2016;430:10-20 pubmed publisher
  152. M L, P P, T K, M P, E S, J P, et al. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol Oncol. 2016;10:735-750 pubmed publisher
  153. Deisting W, Raum T, Kufer P, Baeuerle P, Münz M. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110. PLoS ONE. 2015;10:e0141669 pubmed publisher
  154. Feng Z, Puri S, Moudgil T, Wood W, Hoyt C, Wang C, et al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer. 2015;3:47 pubmed publisher
  155. Akhmetzyanova I, Drabczyk M, Neff C, Gibbert K, Dietze K, Werner T, et al. PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing. PLoS Pathog. 2015;11:e1005224 pubmed publisher
  156. Heigele A, Joas S, Regensburger K, Kirchhoff F. Increased susceptibility of CD4+ T cells from elderly individuals to HIV-1 infection and apoptosis is associated with reduced CD4 and enhanced CXCR4 and FAS surface expression levels. Retrovirology. 2015;12:86 pubmed publisher
  157. Schmidt L, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch J, et al. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS ONE. 2015;10:e0136023 pubmed publisher
  158. Gulati N, Suárez Fariñas M, Correa Da Rosa J, Krueger J. Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions. F1000Res. 2015;4:149 pubmed publisher
  159. Yoon K, Byun S, Kwon E, Hwang S, Chu K, Hiraki M, et al. Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science. 2015;349:1261669 pubmed publisher
  160. Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 2015;9:1773-82 pubmed publisher
  161. James S, Fox J, Afsari F, Lee J, Clough S, Knight C, et al. Multiparameter Analysis of Human Bone Marrow Stromal Cells Identifies Distinct Immunomodulatory and Differentiation-Competent Subtypes. Stem Cell Reports. 2015;4:1004-15 pubmed publisher
  162. Miranda A, Funes J, Sánchez N, Limia C, Mesa M, Quezada S, et al. Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure. Cancer Res. 2015;75:3032-42 pubmed publisher
  163. Rancan C, Schirrmann L, Hüls C, Zeidler R, Moosmann A. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. PLoS Pathog. 2015;11:e1004906 pubmed publisher
  164. Tian X, Zhang A, Qiu C, Wang W, Yang Y, Qiu C, et al. The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects. J Immunol. 2015;194:3873-82 pubmed publisher
  165. Severson J, Serracino H, Mateescu V, Raeburn C, McIntyre R, Sams S, et al. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015;3:620-30 pubmed publisher
  166. Bhela S, Kempsell C, Manohar M, Dominguez Villar M, Griffin R, Bhatt P, et al. Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol. 2015;194:2180-9 pubmed publisher
  167. Du Z, Abedalthagafi M, Aizer A, McHenry A, Sun H, Bray M, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015;6:4704-16 pubmed
  168. Kong L, Wei J, Haider A, Liebelt B, Ling X, Conrad C, et al. Therapeutic targets in subependymoma. J Neuroimmunol. 2014;277:168-75 pubmed publisher
  169. Hautefort A, Girerd B, Montani D, Cohen Kaminsky S, Price L, Lambrecht B, et al. T-helper 17 cell polarization in pulmonary arterial hypertension. Chest. 2015;147:1610-1620 pubmed publisher
  170. Llosa N, Cruise M, Tam A, Wicks E, Hechenbleikner E, Taube J, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43-51 pubmed publisher
  171. Jitschin R, Braun M, Büttner M, Dettmer Wilde K, Bricks J, Berger J, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124:750-60 pubmed publisher
  172. Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS ONE. 2014;9:e88557 pubmed publisher
  173. Barsoum I, Smallwood C, Siemens D, Graham C. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74:665-74 pubmed publisher
  174. Gadiot J, Hooijkaas A, Kaiser A, Van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer. 2011;117:2192-201 pubmed publisher
  175. Raptopoulou A, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010;62:1870-80 pubmed publisher
  176. Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol. 2009;183:4984-93 pubmed publisher
  177. Laudanski K, De A, Miller Graziano C. Exogenous heat shock protein 27 uniquely blocks differentiation of monocytes to dendritic cells. Eur J Immunol. 2007;37:2812-24 pubmed